Development of Hodgkin's lymphoma under bexarotene treatment for Sézary syndrome and review of the literature

J Drugs Dermatol. 2010 Aug;9(8):1014-6.

Abstract

There are several reports of patients who developed extracutaneous lymphoma after they started bexarotene treatment. The authors report a case in which the initiation of bexarotene therapy for Sézary syndrome was temporally associated with the development of Hodgkin's lymphoma despite improvement in cutaneous signs and symptoms. It is possible that bexarotene may contribute to the development of extracutaneous lymphoma. Although bexarotene therapy may relieve symptoms and signs of cutaneous T-cell lymphoma, careful examination of the lymph nodes during treatment is recommended.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anticarcinogenic Agents / adverse effects*
  • Anticarcinogenic Agents / therapeutic use
  • Bexarotene
  • Hodgkin Disease / chemically induced*
  • Humans
  • Male
  • Sezary Syndrome / drug therapy
  • Sezary Syndrome / pathology
  • Tetrahydronaphthalenes / adverse effects*
  • Tetrahydronaphthalenes / therapeutic use

Substances

  • Anticarcinogenic Agents
  • Tetrahydronaphthalenes
  • Bexarotene